Combinations of cholesteryl ester transfer protein inhibitors and HMG CoA reductase inhibitors for cardiovascular indications

Abstract

The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.

What is claimed is:  
     
         1 . A therapeutic combination comprising a first amount of an HMG CoA reductase inhibiting compound and a second amount of a cholesteryl ester transfer protein inhibiting compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount, an anti-atherosclerotic condition effective amount, or an anti-hypercholesterolemic condition effective amount of the compounds.  
     
     
         2 . The therapeutic combination of  claim 1  wherein the HMG CoA reductase inhibiting compound comprises mevastatin.  
     
     
         3 . The therapeutic combination of  claim 1  wherein the HMG CoA reductase inhibiting compound comprises lovastatin.  
     
     
         4 . The therapeutic combination of  claim 1  wherein the HMG CoA reductase inhibiting compound comprises simvastatin.  
     
     
         5 . The therapeutic combination of  claim 1  wherein the HMG CoA reductase inhibiting compound comprises pravastatin.  
     
     
         6 . The therapeutic combination of  claim 1  wherein the HMG CoA reductase inhibiting compound comprises fluvastatin.  
     
     
         7 . The therapeutic combination of  claim 1  wherein the HMG CoA reductase inhibiting compound comprises atorvastatin.  
     
     
         8 . The therapeutic combination of  claim 1  wherein the combination comprises a composition comprising the HMG CoA reductase inhibiting compound and the cholesteryl ester transfer protein inhibiting compound.  
     
     
         9 . A method for the prophylaxis or treatment of a hyperlipidemic condition comprising administering to a patient in need thereof a combination in unit dosage form wherein the combination comprises a first amount of an HMG CoA reductase inhibiting compound and a second amount of a cholesteryl ester transfer protein inhibiting compound wherein the first amount and the second amount together comprise an anti-hyperlipidemic condition effective amount of the compounds.  
     
     
         10 . A method for the prophylaxis or treatment of an atherosclerotic condition comprising administering to a patient in need thereof a combination in unit dosage form wherein the combination comprises a first amount of an HMG CoA reductase inhibiting compound and a second amount of a cholesteryl ester transfer protein inhibiting compound wherein the first amount and the second amount together comprise an anti-atherosclerotic condition effective amount of the compounds.  
     
     
         11 . A method for the prophylaxis or treatment of hypercholesterolemia comprising administering to a patient in need thereof a combination in unit dosage form wherein the combination comprises a first amount of an HMG CoA reductase inhibiting compound and a second amount of a cholesteryl ester transfer protein inhibiting compound wherein the first amount and the second amount together comprise an anti-hypercholesterolemic condition effective amount of the compounds.